v3.26.1
Segment information (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segments      
Revenue € 788,373 € 796,967 € 781,426
Cost of revenue (674,152) (682,086) (606,375)
Gross profit 114,221 114,881 175,051
Operating income and (expenses)      
Research and development (37,509) (50,857) (68,529)
Selling, general and administrative expenses (175,970) (188,201) (169,610)
Impairment/Reversal of impairment of intangible assets     (5,011)
Other operating income 65,599 52,700 64,793
Other operating expenses (21,924) (16,116) (44,202)
Reorganization costs (633) (54,930) 0
Total operating income (expenses) (170,438) (257,403) (222,558)
Operating income (loss) (56,217) (142,522) (47,507)
Revenue from contributions 11,294 14,450 9,417
Discovery & Preclinical Development      
Segments      
Revenue 528,930 611,394 672,977
Operating income and (expenses)      
Revenue from contributions 11,294 12,308 8,461
Just - Evotec Biologics      
Segments      
Revenue 259,443 185,573 108,449
Operating income and (expenses)      
Revenue from contributions   2,142 956
Operating segments | Discovery & Preclinical Development      
Segments      
Cost of revenue (482,470) (509,361) (492,674)
Gross profit 46,811 102,192 180,303
Operating income and (expenses)      
Research and development (37,454) (51,146) (68,529)
Selling, general and administrative expenses (133,248) (158,915) (143,167)
Impairment/Reversal of impairment of intangible assets     108
Other operating income 61,370 49,802 62,524
Other operating expenses (11,327) (13,924) (39,361)
Reorganization costs (633) (54,179)  
Total operating income (expenses) (121,294) (228,362) (188,425)
Operating income (loss) (74,482) (126,170) (8,122)
Depreciation expense 65,291 70,753 64,349
Amortisation expense 9,478 6,484 6,946
Operating segments | Just - Evotec Biologics      
Segments      
Cost of revenue (192,161) (173,068) (113,701)
Gross profit 67,426 13,553 (5,252)
Operating income and (expenses)      
Research and development (72) (576)  
Selling, general and administrative expenses (42,722) (29,286) (26,442)
Impairment/Reversal of impairment of intangible assets     (5,119)
Other operating income 4,230 2,899 2,269
Other operating expenses (10,597) (2,192) (4,841)
Reorganization costs   (751)  
Total operating income (expenses) (49,161) (29,906) (34,133)
Operating income (loss) 18,265 (16,353) (39,385)
Depreciation expense 24,707 24,404 € 21,685
Intersegment eliminations      
Segments      
Revenue (496) (1,208)  
Cost of revenue 479 344  
Gross profit (17) (865)  
Operating income and (expenses)      
Research and development 17 865  
Total operating income (expenses) 17 865  
Intersegment eliminations | Discovery & Preclinical Development      
Segments      
Revenue (352) (160)  
Intersegment eliminations | Just - Evotec Biologics      
Segments      
Revenue € (144) € (1,049)